
Capricor Therapeutics, Inc. is a San Diego based biotechnology company focused on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of muscular and other select diseases. Capricor's lead candidate, CAP-1002, is an allogeneic cardiac-derived cell t... Capricor Therapeutics, Inc. is a San Diego based biotechnology company focused on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of muscular and other select diseases. Capricor's lead candidate, CAP-1002, is an allogeneic cardiac-derived cell therapy that is currently in late-stage clinical development for treating Duchenne muscular dystrophy (DMD). Capricor is also developing its exosome technology as a next-generation therapeutic platform. Capricor's proprietary StealthX¿ exosome platform has potential for a broad range of new therapeutic applications in the field of vaccinology as well as targeted oligonucleotide, protein and small molecule therapeutics to treat or prevent a variety of diseases. 더 보기
기간 | 변동 | 변동 % | 시가 | 고가 | 저가 | 평균 일일 거래량 | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -1.07 | -8.04511278195 | 13.3 | 14.26 | 11.75005 | 2234221 | 12.76682408 | CS |
4 | 1.37 | 12.6151012891 | 10.86 | 15 | 9.53 | 2105851 | 11.89700624 | CS |
12 | -0.97 | -7.34848484848 | 13.2 | 15 | 6.27 | 2263790 | 9.90538317 | CS |
26 | -1.57 | -11.3768115942 | 13.8 | 16.465 | 6.27 | 1714282 | 11.34827926 | CS |
52 | 7.07 | 137.015503876 | 5.16 | 23.4 | 3.52 | 1827220 | 12.67432594 | CS |
156 | 8.18 | 201.975308642 | 4.05 | 23.4 | 2.68 | 736791 | 11.31924477 | CS |
260 | 7.53 | 160.212765957 | 4.7 | 23.4 | 2.56 | 750885 | 9.05955921 | CS |
도움 및 지원받기: kr-support@advfn.com
ADVFN 서비스 이용은 ADVFN의 이용약관에 동의하는 것입니다 이용약관